Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations
Timeline and management
10.1126/science.1068539 Summary Keywords alternative splicing, NADPH formation, endoplasmic reticulum, cytosolic G6PD isoforms, Arabidopsis, metabolons, oxidative pentose phosphate pathway Citation Linnenbrgger L, Doering L, Lansing H, Fischer K, Eirich J, Finkemeier I and von Schaewen A (2022) Alternative splicing of Arabidopsis G6PD5 recruits NADPH-producing OPPP reactions to the endoplasmic reticulum
Private insurers have restricted coverage, or added new approval requirements, and now the state government is doing the same
Wegovy (semaglutide) is a prescription medication used for weight management in adults who have a body mass index (BMI) of 30 or greater
